125 x 125 Static Banner

Hot Nursing Topics

REGISTERED GENERAL NURSE              Newbie :D              Working with people with learning or cognitive impairments              Reflection ofBN506              cognitive impairments              Relections from week 1 and 2              BN506 Reflection              Male hair loss              To Air is Human (COPD Guide)              Balancing Your Life with Congenital Heart Disease
FDA Approves Drug for Patients with Advanced Prostate Cancer Print E-mail
Written by Food and Drug Administration   
Tuesday, 30 December 2008
The U.S. Food and Drug Administration recently approved the injectable drug degarelix, the first new drug  in several years for prostate cancer.

Degarelix is intended to treat patients with advanced prostate cancer. It belongs to a class of agents called gonadotropin releasing hormone (GnRH) receptor inhibitors. These agents slow the growth and progression of prostate cancer by suppressing testosterone, which plays an important role in the continued growth of prostate cancer.

Hormonal treatments for prostate cancer may cause an initial surge in testosterone production before lowering testosterone levels. This initial stimulation of the hormone receptors may temporarily prompt tumor growth rather than inhibiting it. Degarelix doesn't do this.

“Prostate cancer is the second leading cause of cancer death among men in the United States and there is an ongoing need for additional treatment options for these patients,” said Richard Pazdur, M.D., director of the Office of Oncology Drug Products, Center for Drug Evaluation and Research, FDA.

Prostate cancer is one of the most commonly diagnosed cancers in the United States. In 2004, the most recent year for which statistics are currently available, nearly 190,000 men were diagnosed with prostate cancer and 29,000 men died from the cancer.

Several treatment options exist for different stages of prostate cancer including observation, prostatectomy (surgical removal of the prostate gland), radiation therapy, chemotherapy, and hormone therapy with agents that affect GnRH receptors.

The efficacy of degarelix was established in a clinical trial in which patients with prostate cancer received either degarelix or leuprolide, a drug currently used for hormone therapy in treating advanced prostate cancer. Degarelix treatment did not cause the temporary increase in testosterone that is seen with some other drugs that affect GnRH receptors.

In fact, nearly all of the patients on either drug had suppression of testosterone to levels seen with surgical removal of the testes.

The most frequently reported adverse reactions in the clinical study included injection site reactions (pain, redness, and swelling), hot flashes, increased weight, fatigue, and increases in some liver enzymes.

Degarelix is manufactured for Ferring Pharmaceuticals Inc., Parsippany, N.J., by Rentschler Biotechnologie Gmbh, Laupheim, Germany.
Trackback(0)
Comments (1)Add Comment
dxfsdfsd
written by a guest, January 06, 2010

Support of the Lou Zhu, Lou Zhu worked hard
Signature--------------------------------------------------------------------------------------------------------------------
Nothing is impossible for a willing heart.
ugg classic cardy
report abuse
vote down
vote up
Votes: +0

Write comment
quote
bold
italicize
underline
strike
url
image
quote
quote
smile
wink
laugh
grin
angry
sad
shocked
cool
tongue
kiss
cry
smaller | bigger

busy
Last Updated ( Tuesday, 30 December 2008 )
 
Next >

Sponsored Links

  • Travel Nurse Jobs
  • Green LinkUp
  • Carbon LinkUp
  • This e-mail address is being protected from spam bots, you need JavaScript enabled to view it